Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells

Yun Ju Chen, Wei Chien Huang, Ya Ling Wei, Sheng Chieh Hsu, Ping Yuan, Heather Y. Lin, Ignacio I. Wistuba, J. Jack Lee, Chia Jui Yen, Wu Chou Su, Kwang Yu Chang, Wen Chang Chang, Tse Chuan Chou, Chao Kai Chou, Chang Hai Tsai, Mien Chie Hung

研究成果: 雜誌貢獻文章同行評審

69 引文 斯高帕斯(Scopus)

摘要

Background: The sensitivity of non-small cell lung cancer (NSCLC) patients to EGFR tyrosine kinase inhibitors (TKIs) is strongly associated with activating EGFR mutations. Although not as sensitive as patients harboring these mutations, some patients with wild-type EGFR (wtEGFR) remain responsive to EGFR TKIs, suggesting that the existence of unexplored mechanisms renders most of wtEGFR-expressing cancer cells insensitive. Methodology/Principal Findings: Here, we show that acquired resistance of wtEGFR-expressing cancer cells to an EGFR TKI, gefitinib, is associated with elevated expression of breast cancer resistance protein (BCRP/ABCG2), which in turn leads to gefitinib efflux from cells. In addition, BCRP/ABCG2 expression correlates with poor response to gefitinib in both cancer cell lines and lung cancer patients with wtEGFR. Co-treatment with BCRP/ABCG2 inhibitors enhanced the anti-tumor activity of gefitinib. Conclusions/Significance: Thus, BCRP/ABCG2 expression may be a predictor for poor efficacy of gefitinib treatment, and targeting BCRP/ABCG2 may broaden the use of gefitinib in patients with wtEGFR.

原文英語
文章編號e21428
期刊PLoS One
6
發行號6
DOIs
出版狀態已發佈 - 2011
對外發佈Yes

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

指紋 深入研究「Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells」主題。共同形成了獨特的指紋。

引用此